不同PET/CT示踪剂引导的转移性治疗对少复发激素敏感前列腺癌远处和局部疾病控制的影响:precision - mdt研究的二次分析

IF 5.6 Q1 ONCOLOGY
Francesco Lanfranchi, Liliana Belgioia, Domenico Albano, Luca Triggiani, Flavia Linguanti, Luca Urso, Rosario Mazzola, Alessio Rizzo, Elisa D'Angelo, Francesco Dondi, Eneida Mataj, Gloria Pedersoli, Elisabetta Maria Abenavoli, Luca Vaggelli, Beatrice Detti, Naima Ortolan, Antonio Malorgio, Alessia Guarneri, Federico Garrou, Matilde Fiorini, Serena Grimaldi, Pietro Ghedini, Giuseppe Carlo Iorio, Antonella Iudicello, Guido Rovera, Giuseppe Fornarini, Diego Bongiovanni, Michela Marcenaro, Filippo Maria Pazienza, Giorgia Timon, Matteo Salgarello, Manuela Racca, Mirco Bartolomei, Stefano Panareo, Umberto Ricardi, Francesco Bertagna, Filippo Alongi, Salvina Barra, Silvia Morbelli, Gianmario Sambuceti, Matteo Bauckneht
{"title":"不同PET/CT示踪剂引导的转移性治疗对少复发激素敏感前列腺癌远处和局部疾病控制的影响:precision - mdt研究的二次分析","authors":"Francesco Lanfranchi, Liliana Belgioia, Domenico Albano, Luca Triggiani, Flavia Linguanti, Luca Urso, Rosario Mazzola, Alessio Rizzo, Elisa D'Angelo, Francesco Dondi, Eneida Mataj, Gloria Pedersoli, Elisabetta Maria Abenavoli, Luca Vaggelli, Beatrice Detti, Naima Ortolan, Antonio Malorgio, Alessia Guarneri, Federico Garrou, Matilde Fiorini, Serena Grimaldi, Pietro Ghedini, Giuseppe Carlo Iorio, Antonella Iudicello, Guido Rovera, Giuseppe Fornarini, Diego Bongiovanni, Michela Marcenaro, Filippo Maria Pazienza, Giorgia Timon, Matteo Salgarello, Manuela Racca, Mirco Bartolomei, Stefano Panareo, Umberto Ricardi, Francesco Bertagna, Filippo Alongi, Salvina Barra, Silvia Morbelli, Gianmario Sambuceti, Matteo Bauckneht","doi":"10.1148/rycan.240150","DOIUrl":null,"url":null,"abstract":"<p><p>Prospective trials suggest that metastasis-directed therapy (MDT) is an effective treatment for patients with oligometastatic prostate cancer (PCa). Gallium 68 (<sup>68</sup>Ga) prostate-specific membrane antigen (PSMA)-11 PET/CT-guided MDT seems to improve the oncologic outcome in these patients compared with fluorine 18 (<sup>18</sup>F)-fluorocholine and <sup>18</sup>F-PSMA-1007 PET/CT-guided MDT, but the effects in terms of local or distant disease control remain unclear. Thus, the present subanalysis of the PRECISE-MDT study analyzed patients with hormone-sensitive PCa who underwent MDT guided by PET/CT for nodal or bone oligorecurrent disease and were restaged with the same imaging modality in case of biochemical recurrence after MDT. Among 340 lesions detected in 241 male patients (median age, 74 [IQR, 9] years), <sup>18</sup>F-fluorocholine, <sup>68</sup>Ga-PSMA-11, and <sup>18</sup>F-PSMA-1007 PET/CT-guided MDT was performed in 179, 81, and 80 lesions, respectively. At restaging imaging, the PET/CT imaging modality used to guide MDT was not significantly associated with local recurrence-free survival (LRFS), with median LRFS not reached for <sup>68</sup>Ga-PSMA-11 PET/CT, <sup>18</sup>F-PSMA-11 PET/CT, and <sup>18</sup>F-fluorocholine PET/CT (<i>P</i> = .73). However, the detection rate of a new metastasis was significantly higher if MDT was guided by <sup>18</sup>F-fluorocholine PET/CT (119 of 179 lesions, 66.5%) compared with <sup>68</sup>Ga-PSMA-11 or <sup>18</sup>F-PSMA-1007 PET/CT (23 of 81 lesions, 28%, and 27 of 80, 34%, respectively; <i>P</i> < .001 for both). Moreover, MDT guided by <sup>68</sup>Ga-PSMA-11 PET/CT led to an improved median metastasis-free survival (MFS) (not reached) compared with <sup>18</sup>F-PSMA-1007 (median MFS, 24.9 months; <i>P</i> < .001) or <sup>18</sup>F-fluorocholine PET/CT (median MFS, 18 months; <i>P</i> < .001). These findings suggest that using different PET/CT imaging modalities to guide MDT might impact the distant disease control in this clinical scenario. <b>Keywords:</b> Radiation Therapy, Oncology, Urinary, Prostate, PET/CT <i>Supplemental material is available for this article.</i> Published under a CC BY 4.0 license.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"7 3","pages":"e240150"},"PeriodicalIF":5.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Metastasis-directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT Study.\",\"authors\":\"Francesco Lanfranchi, Liliana Belgioia, Domenico Albano, Luca Triggiani, Flavia Linguanti, Luca Urso, Rosario Mazzola, Alessio Rizzo, Elisa D'Angelo, Francesco Dondi, Eneida Mataj, Gloria Pedersoli, Elisabetta Maria Abenavoli, Luca Vaggelli, Beatrice Detti, Naima Ortolan, Antonio Malorgio, Alessia Guarneri, Federico Garrou, Matilde Fiorini, Serena Grimaldi, Pietro Ghedini, Giuseppe Carlo Iorio, Antonella Iudicello, Guido Rovera, Giuseppe Fornarini, Diego Bongiovanni, Michela Marcenaro, Filippo Maria Pazienza, Giorgia Timon, Matteo Salgarello, Manuela Racca, Mirco Bartolomei, Stefano Panareo, Umberto Ricardi, Francesco Bertagna, Filippo Alongi, Salvina Barra, Silvia Morbelli, Gianmario Sambuceti, Matteo Bauckneht\",\"doi\":\"10.1148/rycan.240150\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prospective trials suggest that metastasis-directed therapy (MDT) is an effective treatment for patients with oligometastatic prostate cancer (PCa). Gallium 68 (<sup>68</sup>Ga) prostate-specific membrane antigen (PSMA)-11 PET/CT-guided MDT seems to improve the oncologic outcome in these patients compared with fluorine 18 (<sup>18</sup>F)-fluorocholine and <sup>18</sup>F-PSMA-1007 PET/CT-guided MDT, but the effects in terms of local or distant disease control remain unclear. Thus, the present subanalysis of the PRECISE-MDT study analyzed patients with hormone-sensitive PCa who underwent MDT guided by PET/CT for nodal or bone oligorecurrent disease and were restaged with the same imaging modality in case of biochemical recurrence after MDT. Among 340 lesions detected in 241 male patients (median age, 74 [IQR, 9] years), <sup>18</sup>F-fluorocholine, <sup>68</sup>Ga-PSMA-11, and <sup>18</sup>F-PSMA-1007 PET/CT-guided MDT was performed in 179, 81, and 80 lesions, respectively. At restaging imaging, the PET/CT imaging modality used to guide MDT was not significantly associated with local recurrence-free survival (LRFS), with median LRFS not reached for <sup>68</sup>Ga-PSMA-11 PET/CT, <sup>18</sup>F-PSMA-11 PET/CT, and <sup>18</sup>F-fluorocholine PET/CT (<i>P</i> = .73). However, the detection rate of a new metastasis was significantly higher if MDT was guided by <sup>18</sup>F-fluorocholine PET/CT (119 of 179 lesions, 66.5%) compared with <sup>68</sup>Ga-PSMA-11 or <sup>18</sup>F-PSMA-1007 PET/CT (23 of 81 lesions, 28%, and 27 of 80, 34%, respectively; <i>P</i> < .001 for both). Moreover, MDT guided by <sup>68</sup>Ga-PSMA-11 PET/CT led to an improved median metastasis-free survival (MFS) (not reached) compared with <sup>18</sup>F-PSMA-1007 (median MFS, 24.9 months; <i>P</i> < .001) or <sup>18</sup>F-fluorocholine PET/CT (median MFS, 18 months; <i>P</i> < .001). These findings suggest that using different PET/CT imaging modalities to guide MDT might impact the distant disease control in this clinical scenario. <b>Keywords:</b> Radiation Therapy, Oncology, Urinary, Prostate, PET/CT <i>Supplemental material is available for this article.</i> Published under a CC BY 4.0 license.</p>\",\"PeriodicalId\":20786,\"journal\":{\"name\":\"Radiology. Imaging cancer\",\"volume\":\"7 3\",\"pages\":\"e240150\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiology. Imaging cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1148/rycan.240150\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology. Imaging cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1148/rycan.240150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

前瞻性试验表明,转移导向治疗(MDT)是治疗少转移性前列腺癌(PCa)患者的有效方法。与氟18 (18F)-氟胆碱和18F-PSMA-1007 PET/ ct引导MDT相比,镓68 (68Ga)前列腺特异性膜抗原(PSMA)-11 PET/ ct引导MDT似乎改善了这些患者的肿瘤预后,但在局部或远处疾病控制方面的效果尚不清楚。因此,本次precision -MDT研究的亚分析分析了激素敏感性PCa患者,这些患者在PET/CT引导下接受了淋巴结或骨少复发疾病的MDT,并在MDT后进行了相同的影像学检查。241例男性患者(中位年龄74岁[IQR, 9]岁)共检出340个病灶,其中PET/ ct引导下行18f -氟胆碱、68Ga-PSMA-11和18F-PSMA-1007 MDT的病灶分别为179个、81个和80个。在再分期成像时,用于指导MDT的PET/CT成像方式与局部无复发生存期(LRFS)无显著相关性,68Ga-PSMA-11 PET/CT、18F-PSMA-11 PET/CT和18f -氟胆碱PET/CT的中位LRFS未达到(P = 0.73)。然而,与68Ga-PSMA-11或18F-PSMA-1007 PET/CT(81例中有23例,28%,80例中有27例,34%)相比,18f -氟胆碱PET/CT引导下MDT的新转移检出率明显更高(179例中有119例,66.5%);P < 0.001)。此外,68Ga-PSMA-11 PET/CT引导下的MDT与18F-PSMA-1007(中位MFS, 24.9个月;P < 0.001)或18f -氟胆碱PET/CT(中位MFS, 18个月;P < 0.001)。这些发现表明,在这种临床情况下,使用不同的PET/CT成像方式指导MDT可能会影响远处疾病的控制。关键词:放射治疗,肿瘤,泌尿,前列腺,PET/CT本文有补充资料。在CC BY 4.0许可下发布。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Metastasis-directed Therapy Guided by Different PET/CT Radiotracers on Distant and Local Disease Control in Oligorecurrent Hormone-sensitive Prostate Cancer: A Secondary Analysis of the PRECISE-MDT Study.

Prospective trials suggest that metastasis-directed therapy (MDT) is an effective treatment for patients with oligometastatic prostate cancer (PCa). Gallium 68 (68Ga) prostate-specific membrane antigen (PSMA)-11 PET/CT-guided MDT seems to improve the oncologic outcome in these patients compared with fluorine 18 (18F)-fluorocholine and 18F-PSMA-1007 PET/CT-guided MDT, but the effects in terms of local or distant disease control remain unclear. Thus, the present subanalysis of the PRECISE-MDT study analyzed patients with hormone-sensitive PCa who underwent MDT guided by PET/CT for nodal or bone oligorecurrent disease and were restaged with the same imaging modality in case of biochemical recurrence after MDT. Among 340 lesions detected in 241 male patients (median age, 74 [IQR, 9] years), 18F-fluorocholine, 68Ga-PSMA-11, and 18F-PSMA-1007 PET/CT-guided MDT was performed in 179, 81, and 80 lesions, respectively. At restaging imaging, the PET/CT imaging modality used to guide MDT was not significantly associated with local recurrence-free survival (LRFS), with median LRFS not reached for 68Ga-PSMA-11 PET/CT, 18F-PSMA-11 PET/CT, and 18F-fluorocholine PET/CT (P = .73). However, the detection rate of a new metastasis was significantly higher if MDT was guided by 18F-fluorocholine PET/CT (119 of 179 lesions, 66.5%) compared with 68Ga-PSMA-11 or 18F-PSMA-1007 PET/CT (23 of 81 lesions, 28%, and 27 of 80, 34%, respectively; P < .001 for both). Moreover, MDT guided by 68Ga-PSMA-11 PET/CT led to an improved median metastasis-free survival (MFS) (not reached) compared with 18F-PSMA-1007 (median MFS, 24.9 months; P < .001) or 18F-fluorocholine PET/CT (median MFS, 18 months; P < .001). These findings suggest that using different PET/CT imaging modalities to guide MDT might impact the distant disease control in this clinical scenario. Keywords: Radiation Therapy, Oncology, Urinary, Prostate, PET/CT Supplemental material is available for this article. Published under a CC BY 4.0 license.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.00
自引率
2.30%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信